{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:40:35Z","timestamp":1783438835342,"version":"3.54.6"},"reference-count":67,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.clml.2016.08.019","type":"journal-article","created":{"date-parts":[[2016,9,4]],"date-time":"2016-09-04T17:49:57Z","timestamp":1473011397000},"page":"662-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Total Skin Electron Beam Therapy in the Treatment of Mycosis Fungoides: A Review of Conventional and Low-Dose Regimens"],"prefix":"10.1016","volume":"16","author":[{"given":"Mudit","family":"Chowdhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit M.","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Kharod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.08.019_bib1","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.019_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e31825494d3","article-title":"Treatment of mycosis fungoides with total skin electron beam: response and relapse by ethnicity and sex","volume":"36","author":"Hinds","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.019_bib3","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.019_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2006.1.323","article-title":"Primary cutaneous T-cell lymphomas","volume":"513","author":"Rosen","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2016.08.019_bib5","series-title":"Pathology and Genetics: Skin Tumors","author":"Leboit","year":"2005"},{"key":"10.1016\/j.clml.2016.08.019_bib6","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2016.08.019_bib7","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1111\/j.1440-0960.1997.tb01018.x","article-title":"Mycosis fungoides: an Australian experience","volume":"38","author":"Yen","year":"1997","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1991.9.7.1298","article-title":"Mycosis fungoides and the S\u00e9zary syndrome: a review of pathogenesis, diagnosis, and therapy","volume":"9","author":"Kuzel","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.019_bib9","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.019_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2016.08.019_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1396-0296.2003.01641.x","article-title":"Topical carmustine (BCNU) in the treatment of mycosis fungoides","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clml.2016.08.019_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib14","first-page":"391","article-title":"Topical imiquimod as treatment for different kinds of cutaneous lymphoma","volume":"16","author":"Coors","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.019_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2016.08.019_bib19","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.019_bib20","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.019_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clml.2016.08.019_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0014-2964(77)90107-4","article-title":"Blood and bone marrow response following total body irradiation in patients with lymphosarcomas","volume":"119","author":"Qasim","year":"1977","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2016.08.019_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/path.1700640403","article-title":"The sensitivity of lymphocytes to ionizing radiation","volume":"64","author":"Trowell","year":"1952","journal-title":"J\u00a0Pathol Bacteriol"},{"key":"10.1016\/j.clml.2016.08.019_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1148\/119.2.439","article-title":"Dose\u2013time fractionation study in patients with mycosis fungoides and lymphoma cutis","volume":"119","author":"Kim","year":"1976","journal-title":"Radiology"},{"key":"10.1016\/j.clml.2016.08.019_bib25","series-title":"Radiobiology for the Radiologist","author":"Hall","year":"2006"},{"key":"10.1016\/j.clml.2016.08.019_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1102\/1470-7330.2005.0012","article-title":"Complications of radiotherapy: improving the therapeutic index","volume":"5","author":"Beasley","year":"2005","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.clml.2016.08.019_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group","volume":"47","author":"Jones","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib28","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: non-Hodgkin's lymphomas, version 3.2016. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf. Accessed: July 1, 2016."},{"key":"10.1016\/j.clml.2016.08.019_bib29","first-page":"623","article-title":"High energy electrons for the treatment of extensive superficial malignant lesions","volume":"69","author":"Trump","year":"1953","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"10.1016\/j.clml.2016.08.019_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1148\/74.4.633","article-title":"A\u00a0technique for large-field, superficial electron therapy","volume":"74","author":"Karzmark","year":"1960","journal-title":"Radiology"},{"key":"10.1016\/j.clml.2016.08.019_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1118\/1.595296","article-title":"Physical aspects of a rotational total skin electron irradiation","volume":"10","author":"Podgorsak","year":"1983","journal-title":"Med Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1507-1367(06)71047-1","article-title":"The rotary dual technique for total skin irradiation in the treatment of mycosis fungoides\u2014a description of the applied method","volume":"11","author":"Piotrowski","year":"2006","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.clml.2016.08.019_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5114\/pdia.2013.33379","article-title":"Total skin electron irradiation techniques: a review","volume":"30","author":"Piotrowski","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.clml.2016.08.019_bib34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0360-3016(90)90075-U","article-title":"Development of total-skin electron therapy at two energies","volume":"18","author":"Cox","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0360-3016(95)00161-Q","article-title":"Evaluation of dose variation during total skin electron irradiation using thermoluminescent dosimeters","volume":"33","author":"Weaver","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib37","doi-asserted-by":"crossref","first-page":"070903","DOI":"10.1118\/1.4811216","article-title":"In\u00a0vivo dosimetry in external beam radiotherapy","volume":"40","author":"Mijnheer","year":"2013","journal-title":"Med Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0360-3016(80)90070-X","article-title":"Individualized eye shields for use in electron beam therapy as well as low-energy photon irradiation","volume":"6","author":"Asbell","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0360-3016(88)90306-9","article-title":"Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites","volume":"15","author":"Desai","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaad.2013.04.063","article-title":"Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides","volume":"69","author":"Lloyd","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0190-9622(86)70128-X","article-title":"Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides","volume":"14","author":"Abel","year":"1986","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib42","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/archderm.1995.01690160060009","article-title":"Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation","volume":"131","author":"Licata","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib43","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0360-3016(94)00590-H","article-title":"Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides","volume":"32","author":"Becker","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0190-9622(96)90499-5","article-title":"Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma","volume":"35","author":"Wilson","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib45","first-page":"1985","article-title":"Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the S\u00e9zary syndrome)","volume":"85","author":"Jones","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.08.019_bib46","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0360-3016(94)90103-1","article-title":"Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 Gy","volume":"28","author":"Jones","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quiros","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib48","first-page":"275","article-title":"Total skin electron beam therapy (TSEBT) in the management of mycosis fungoides: single institution experience","volume":"15","author":"Shouman","year":"2003","journal-title":"J\u00a0Egypt Natl Cancer Inst"},{"key":"10.1016\/j.clml.2016.08.019_bib49","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ijrobp.2003.08.007","article-title":"Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation)","volume":"58","author":"Ysebaert","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib51","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low-dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijrobp.2015.01.047","article-title":"Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis","volume":"92","author":"Kamstrup","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib54","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2015.08.041","article-title":"Total skin electron beam for primary cutaneous T-cell lymphoma","volume":"93","author":"Elsayad","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib55","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0360-3016(77)90182-1","article-title":"The rationale for curative radiotherapy in mycosis fungoides","volume":"2","author":"Hoppe","year":"1977","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib56","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2016.08.019_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/COC.0b013e3181841f5c","article-title":"Patient perspectives regarding the value of total skin electron beam therapy for cutaneous T-cell lymphoma\/mycosis fungoides: a pilot study","volume":"32","author":"Yu","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.019_bib58","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2147\/OTT.S87219","article-title":"Rapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapy","volume":"8","author":"Chowdhary","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2016.08.019_bib59","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.019_bib60","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.019_bib61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","article-title":"Modulation of radiation response by histone deacetylase inhibition","volume":"62","author":"Chinnaiyan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2016.08.019_bib62","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-09-0038","article-title":"Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in\u00a0vitro and as intracranial xenografts","volume":"8","author":"Baschnagel","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2016.08.019_bib63","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","article-title":"Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma","volume":"103","author":"Vowels","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib64","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A\u00a0phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2016.08.019_bib65","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.019_bib66","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.019_bib67","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016304943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016304943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T22:43:59Z","timestamp":1582584239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016304943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S2152265016304943"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Total Skin Electron Beam Therapy in the Treatment of Mycosis Fungoides: A Review of Conventional and Low-Dose Regimens","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}